CARMEL, Ind., Feb. 23, 2026 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, today announced that Kent Hawryluk, President and Chief Executive Officer, and Sam Azoulay, M.D., Chief Medical Officer, will participate in the following upcoming March investor conferences: Citizens Life Sciences Conference Date ...

Core Insights - MBX Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on precision peptide therapies for endocrine and metabolic disorders [1][3] - The company will participate in two upcoming investor conferences, providing opportunities for engagement with investors [2] Company Overview - MBX Biosciences specializes in the discovery, development, and commercialization of novel precision peptide therapies using its proprietary PEP™ platform [3] - The company is advancing a pipeline that includes canvuparatide (MBX 2109) for chronic hypoparathyroidism, which is preparing for Phase 3 development [3] - The obesity portfolio includes MBX 4291 in Phase 1 development and several discovery and pre-clinical candidates [3] - Imapextide (MBX 1416) is in Phase 2 development for post-bariatric hypoglycemia [3] - The company is based in Carmel, Indiana [3]

Core Insights - MBX Biosciences, Inc. has appointed Laurie Stelzer as an independent director and chairperson of the audit committee, bringing extensive executive and financial leadership experience [1][2] - The company is focused on developing precision peptide therapies for endocrine and metabolic disorders, with a strong pipeline and a catalyst-rich year ahead [2][3] Company Overview - MBX Biosciences specializes in the discovery, development, and commercialization of novel precision peptide therapies using its proprietary PEP™ platform [3] - The company is advancing a pipeline that includes canvuparatide (MBX 2109) for chronic hypoparathyroidism, an obesity portfolio with MBX 4291 in Phase 1, and imapextide (MBX 1416) for post-bariatric hypoglycemia in Phase 2 [3] Leadership and Governance - Laurie Stelzer has over 25 years of experience in finance and leadership roles across various biopharmaceutical companies, including previous positions as CFO at multiple firms [2] - Stelzer's expertise is expected to enhance the company's governance and strategic direction as it progresses through clinical trials [2]

Company Overview - MBX Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing novel precision peptide therapies for endocrine and metabolic disorders [3] - The company is based in Carmel, Indiana and utilizes its proprietary PEP™ platform for drug discovery [3] Pipeline Development - MBX Biosciences is advancing a pipeline that includes canvuparatide (MBX 2109) for chronic hypoparathyroidism, which is preparing for Phase 3 development [3] - The obesity portfolio includes MBX 4291, currently in Phase 1 development, along with multiple discovery and pre-clinical candidates [3] - Imapextide (MBX 1416) is in Phase 2 development for post-bariatric hypoglycemia [3] Upcoming Events - Kent Hawryluk, President and CEO, will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco from January 12-15, 2026 [1] - The company presentation is scheduled for January 13, 2026, at 3:45 p.m. PT/6:45 p.m. ET [2] - A live webcast of the presentation will be available on the MBX Biosciences website, with a replay accessible for approximately 90 days [2]

Core Viewpoint - MBX Biosciences has submitted an Investigational New Drug (IND) application to the FDA for MBX 4291, a long-acting GLP-1/GIP receptor co-agonist prodrug aimed at treating obesity, with a Phase 1 trial expected to start in Q3 2025 [2][3][4] Company Overview - MBX Biosciences is a clinical-stage biopharmaceutical company focused on developing novel precision peptide therapies for endocrine and metabolic disorders [6] - The company is based in Carmel, Indiana, and is advancing a pipeline that includes multiple candidates for obesity and other metabolic disorders [6] Product Details - MBX 4291 is designed as a once-monthly injectable treatment for obesity, potentially offering improved gastrointestinal tolerability and better adherence compared to existing treatments [3][4] - Preclinical studies indicate that MBX 4291 has a similar activity profile and body weight loss effect as tirzepatide, an approved weekly GLP-1/GIP co-agonist, with an extended duration of action [5] Development Pipeline - The company is advancing several early-stage obesity candidates alongside MBX 4291, utilizing its proprietary PEP™ platform to create precision peptides with differentiating characteristics [3][6] - Other candidates in the pipeline include canvuparatide (MBX 2109) in Phase 2 for chronic hypoparathyroidism and imapextide (MBX 1416) in Phase 1 for post-bariatric hypoglycemia [6] Proprietary Technology - MBX's PEP™ platform is designed to enhance peptide drug design, aiming to overcome limitations of traditional peptide therapies by optimizing pharmaceutical properties such as extended action profiles and consistent drug concentrations [7]